How Body Composition Affects Radiation Dosing in Prostate Cancer Treatment
Part of Cancer, Kidney & urinary clinical trials.
This study examines how body composition (muscle, fat, bone) impacts the dosing and effectiveness of a radioactive treatment called 177Lu-PSMA for advanced prostate cancer. The goal is to help doctors personalize treatment doses based on individual patient characteristics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male patient age 18 or older
- You have been diagnosed with prostate cancer (adenocarcinoma) confirmed by biopsy
- Your doctor and medical team have decided you are a candidate for 177Lu-PSMA radioligand therapy
- A PET/CT scan has confirmed PSMA expression (a protein marker) in your tumor
- You are enrolled in or eligible for social security/health insurance coverage
- You are able to understand the study requirements and comply with study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.